Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Beijing banned imports of Illumina’s gene-sequencing machines in response to U.S. tariffs.
China hits Illumina with import ban. What does that mean for the San Diego gene sequencer?
China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...
Illumina to cut $100M in costs to cope with China ban
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
China Bans Illumina Sequencer Imports as Trade Tensions Rise
China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory measures against fresh US ...
Illumina addresses recent developments in China
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...
Investing7d
Illumina’s SWOT analysis: next-gen sequencing leader faces headwinds
Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...
MedTech Dive13d
Illumina’s DNA sequencers hit with China import ban
Illumina is not banned from operating in the country and will continue to serve its existing customers, a company ...
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today ...
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...
Investing7d
Illumina’s SWOT analysis: next-gen sequencing leader faces headwinds
Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...
Wall Street Journal8d
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...
Illumina Unusual Options Activity
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...